Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

Treatment options for pulmonary arterial hypertension (PAH) have considerably improved in the past few years. Endothelin (ET)-receptor antagonism has been established as a first-line option for the majority of PAH patients. Endothelin-receptor antagonists (ETRAs) comprise sulfonamide and non-sulfona...

Descripción completa

Detalles Bibliográficos
Autores principales: Opitz, Christian F., Ewert, Ralf, Kirch, Wilhelm, Pittrow, David
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515885/
https://www.ncbi.nlm.nih.gov/pubmed/18562303
http://dx.doi.org/10.1093/eurheartj/ehn234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515885/
https://www.ncbi.nlm.nih.gov/pubmed/18562303
http://dx.doi.org/10.1093/eurheartj/ehn234

Ejemplares similares